FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883745811> ?p ?o ?g. }

• W2883745811 endingPage "2150" @default.
• W2883745811 startingPage "2141" @default.
• W2883745811 abstract "Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis Yi Que,1,* Yao Liang,2,* Jingjing Zhao,1 Ya Ding,1 Ruiqing Peng,1 Yuanxiang Guan,2 Xing Zhang1 1Department of Medical Melanoma and Sarcoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China; 2Department of Gastric and Pancreatic Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, People’s Republic of China *These authors contributed equally to this work Objective: Research efforts have investigated therapies targeting tyrosine kinase signaling pathways. We performed a pooled analysis to determine the frequency of severe adverse effects in patients with soft tissue sarcoma treated with pazopanib, sorafenib and sunitinib. Materials and methods: We performed a comprehensive search of PubMed, Web of Science, Ovid, the Cochrane Library and Embase databases from the drugs’ inception to May 2017 to identify clinical trials. All-grade and severe adverse events (AEs; grade≥3) were analyzed. Results: A total of 10 trials published between 2009 and 2016, including 843 patients, were eligible for analysis. We included 424 patients (three studies) who received pazopanib 800 mg daily, 353 patients (five studies) who received sorafenib 400 mg twice daily and 66 patients (two studies) who received sunitinib 37.5 mg daily. The incidence of AEs is different among the three VEGFR-tyrosine kinase inhibitors (TKIs). Pazopanib showed higher incidence of all-grade nausea, diarrhea and hypertension compared with sorafenib and sunitinib. However, patients in the sorafenib group experienced a significantly higher frequency of all-grade rash (26.1%), hand–foot syndrome (33.4%) and mucositis (38.5%). The difference was highly significant for sorafenib vs. pazopanib in the incidence of all-grade rash (odds ratio [OR] 1.649, 95% CI 1.086–2.505, P=0.023), hand–foot syndrome (OR 3.096, 95% CI 1.271–7.544, P=0.009) and mucositis (OR 4.562, 95% CI 2.132–9.609, P<0.001). Moreover, the frequency of grade ≥3 mucositis was significantly higher in the sunitinib group compared with the pazopanib or sorafenib group (7.6% vs. 1.3%, OR 6.448, 95% CI 1.499–27.731, P=0.013). Conclusion: Statistically significant differences in certain common adverse effects, such as all-grade and severe AEs, were detected among pazopanib, sorafenib and sunitinib in the current study. Early and prompt management is critically needed to avoid unnecessary dose reductions and treatment-related discontinuations. Keywords: pazopanib, sorafenib, sunitinib, soft tissue sarcoma" @default.
• W2883745811 created "2018-08-03" @default.
• W2883745811 creator A5032975188 @default.
• W2883745811 creator A5034291484 @default.
• W2883745811 creator A5050803462 @default.
• W2883745811 creator A5059368310 @default.
• W2883745811 creator A5078634382 @default.
• W2883745811 creator A5082272658 @default.
• W2883745811 creator A5087840544 @default.
• W2883745811 date "2018-07-01" @default.
• W2883745811 modified "2023-10-17" @default.
• W2883745811 title "Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis" @default.
• W2883745811 cites W1604072687 @default.
• W2883745811 cites W1608729829 @default.
• W2883745811 cites W1851856540 @default.
• W2883745811 cites W1971527941 @default.
• W2883745811 cites W1971610159 @default.
• W2883745811 cites W1971837077 @default.
• W2883745811 cites W1980715318 @default.
• W2883745811 cites W1988519149 @default.
• W2883745811 cites W1999662775 @default.
• W2883745811 cites W1999966467 @default.
• W2883745811 cites W2003278910 @default.
• W2883745811 cites W2007431337 @default.
• W2883745811 cites W2016576372 @default.
• W2883745811 cites W2026888006 @default.
• W2883745811 cites W2030541266 @default.
• W2883745811 cites W2032881002 @default.
• W2883745811 cites W2049455380 @default.
• W2883745811 cites W2064583395 @default.
• W2883745811 cites W2075867443 @default.
• W2883745811 cites W2081887573 @default.
• W2883745811 cites W2088018126 @default.
• W2883745811 cites W2093433762 @default.
• W2883745811 cites W2098923148 @default.
• W2883745811 cites W2101776780 @default.
• W2883745811 cites W2107230638 @default.
• W2883745811 cites W2109740762 @default.
• W2883745811 cites W2111141701 @default.
• W2883745811 cites W2115966993 @default.
• W2883745811 cites W2116177733 @default.
• W2883745811 cites W2133365073 @default.
• W2883745811 cites W2135867254 @default.
• W2883745811 cites W2139120013 @default.
• W2883745811 cites W2139511378 @default.
• W2883745811 cites W2142170680 @default.
• W2883745811 cites W2144530818 @default.
• W2883745811 cites W2148064549 @default.
• W2883745811 cites W2153331460 @default.
• W2883745811 cites W2153616752 @default.
• W2883745811 cites W2156437499 @default.
• W2883745811 cites W2158474413 @default.
• W2883745811 cites W2162424705 @default.
• W2883745811 cites W2165671989 @default.
• W2883745811 cites W2170583701 @default.
• W2883745811 cites W2517108090 @default.
• W2883745811 cites W2551773592 @default.
• W2883745811 cites W2588681363 @default.
• W2883745811 cites W2735842687 @default.
• W2883745811 cites W4244991725 @default.
• W2883745811 doi "https://doi.org/10.2147/cmar.s164535" @default.
• W2883745811 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6055834" @default.
• W2883745811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30050324" @default.
• W2883745811 hasPublicationYear "2018" @default.
• W2883745811 type Work @default.
• W2883745811 sameAs 2883745811 @default.
• W2883745811 citedByCount "22" @default.
• W2883745811 countsByYear W28837458112018 @default.
• W2883745811 countsByYear W28837458112019 @default.
• W2883745811 countsByYear W28837458112020 @default.
• W2883745811 countsByYear W28837458112021 @default.
• W2883745811 countsByYear W28837458112022 @default.
• W2883745811 countsByYear W28837458112023 @default.
• W2883745811 crossrefType "journal-article" @default.
• W2883745811 hasAuthorship W2883745811A5032975188 @default.
• W2883745811 hasAuthorship W2883745811A5034291484 @default.
• W2883745811 hasAuthorship W2883745811A5050803462 @default.
• W2883745811 hasAuthorship W2883745811A5059368310 @default.
• W2883745811 hasAuthorship W2883745811A5078634382 @default.
• W2883745811 hasAuthorship W2883745811A5082272658 @default.
• W2883745811 hasAuthorship W2883745811A5087840544 @default.
• W2883745811 hasBestOaLocation W28837458111 @default.
• W2883745811 hasConcept C121608353 @default.
• W2883745811 hasConcept C126322002 @default.
• W2883745811 hasConcept C142724271 @default.
• W2883745811 hasConcept C143998085 @default.
• W2883745811 hasConcept C197934379 @default.
• W2883745811 hasConcept C2778019345 @default.
• W2883745811 hasConcept C2778256501 @default.
• W2883745811 hasConcept C2778439243 @default.
• W2883745811 hasConcept C2778629024 @default.
• W2883745811 hasConcept C2778695046 @default.
• W2883745811 hasConcept C2779490328 @default.
• W2883745811 hasConcept C71924100 @default.
• W2883745811 hasConceptScore W2883745811C121608353 @default.
• W2883745811 hasConceptScore W2883745811C126322002 @default.
• W2883745811 hasConceptScore W2883745811C142724271 @default.
• W2883745811 hasConceptScore W2883745811C143998085 @default.

• next